The ACE2 Knockout A2780 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population of A2780 human epithelial ovarian carcinoma cells with targeted disruption of the ACE2 gene. This heterogeneous pool lacks wild-type ACE2 protein expression, offering a robust loss-of-function model free from clonal selection artifacts. The product is provided as a mixture of edited cells, enabling researchers to investigate ACE2-dependent biology in a physiologically relevant ovarian cancer cell background.
The parental A2780 cell line is a well-characterized model of high-grade serous ovarian carcinoma, established from an untreated patient and noted for its cisplatin sensitivity. It recapitulates key molecular and cellular features of ovarian cancer and is widely employed for studying gene function, drug response, and signaling pathways in gynecologic malignancies. Its stable growth and genomic integrity make it an ideal host for CRISPR-based knockout generation, ensuring reproducible and interpretable experimental outcomes.
ACE2 is a carboxypeptidase that converts angiotensin II to angiotensin-(1-7), a vasodilator acting via the Mas receptor, and functions downstream of renin and ACE. Its expression is regulated by interferon signaling, HIF-1??, and shedding by ADAM17. ACE2 also serves as the SARS-CoV-2 receptor, binding the spike protein and cooperating with TMPRSS2 for clathrin-mediated viral entry. Thus, ACE2 links RAS-mediated vasoregulation with viral pathogenesis, impacting hypertension, heart failure, and ARDS.
In ovarian cancer, ACE2 may modulate the tumor microenvironment via local angiotensin peptide regulation. The A2780 knockout model permits dissection of ACE2’s role in ovarian carcinoma cell proliferation, migration, and therapy response. Additionally, as A2780 cells support SARS-CoV-2 pseudovirus entry, the knockout line enables investigation of viral tropism and host-pathogen interactions in a cancer context. Loss of ACE2 allows focused analysis of signaling pathways such as Ang II/AT1R and Ang-(1-7)/Mas receptor, bridging oncology and virology research.
Key applications include SARS-CoV-2 spike entry studies, pseudovirus neutralization, RAS drug evaluation, and ACE2 signaling in ovarian cancer. Standard assays comprise western blotting, RT-qPCR, flow cytometry, ACE2 enzymatic activity, co-immunoprecipitation, immunofluorescence, and angiotensin mass spectrometry. These polyclonal knockout cells thus serve as a multi-disciplinary tool for virology, cardiovascular pharmacology, and oncology. For further information, please contact Ascent Research.
